製剤技術とGMPの最先端技術情報

ロンザ株式会社 受託製造開発事業部 Lonza Pharma & Biotech     

[細胞・遺伝子治療] Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates

2020/05/25

・Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipeline
・Manufacturing to take place at Lonza’s GMP site in Geleen, Netherlands


Basel, Switzerland and New York, October 1, 2019 – Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), and Lonza (SWX: LONN), announced today that the companies have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates targeting hematological malignancies. Lonza is in charge of implementing Cellectis’ manufacturing processes as per current Good Manufacturing Practices (cGMP) in a way that meets the highest quality and safety standards outlined by the FDA. The manufacturing will take place at Lonza's GMP facility in Geleen, Netherlands.
William Monteith, Executive President, Technical Operations, Cellectis:
“Working with Lonza, a world-class solutions provider with deep experience in the biotech and pharma industries increases our global capabilities and allows Cellectis to further strengthen its manufacturing expertise. This agreement not only bolsters our product supply for clinical trials, but it ensures that we are producing first-rate product candidates so that we can potentially deliver new hope to patients living with certain blood cancers.”

William Monteith, Executive President, Technical Operations, Cellectis:
“Working with Lonza, a world-class solutions provider with deep experience in the biotech and pharma industries increases our global capabilities and allows Cellectis to further strengthen its manufacturing expertise. This agreement not only bolsters our product supply for clinical trials, but it ensures that we are producing first-rate product candidates so that we can potentially deliver new hope to patients living with certain blood cancers.”

Alberto Santagostino, Senior Vice President, Head of Cell & Gene Technologies, Lonza:
“Early-stage innovators with great science, like Cellectis, can find an ideal partner in Lonza as we bring great value in technical development and manufacturing, industrializing processes and enabling the journey to commercialization. We will draw on the experience at our cell and gene therapy center of excellence in the Netherlands, ideally equipped to support Cellectis in bringing their promising pipeline of allogeneic CAR-T therapies to people around the world in need of life-saving products.”
Lonza's supply will complement Cellectis' ongoing collaboration and in-house manufacturing sites, IMPACT and SMART, which are currently under construction.
The manufacturing process of Cellectis’ allogeneic CAR T-cell product line, Universal CARTs or UCARTs, yields frozen, off-the-shelf, non-alloreactive engineered CAR T-cells. UCARTs are intended to be readily available CAR T-cells for a large patient population. Their production is industrialized with defined pharmaceutical release criteria.
(リンク先より全文をご覧いただけます/英語)

企業情報

ロンザ株式会社 受託製造開発事業部 Lonza Pharma & Biotech     

詳しく見る

このリリースに関連する商材情報

業界トピック

TOP